Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-865 in drug-resistant focal onset seizures
NCT04686786Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of darigabat in epilepsy, sponsored by AbbVie Inc.. Started Dec 2020; status: terminated.
02
Drugs
darigabat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04686786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04686786.